Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yoshihiko Tomita, Robert J. Motzer, Toni K. Choueiri, Brian I. Rini, Hideaki Miyake, Mototsugu Oya, Laurence Albiges, Yosuke Fujii, Yoshiko Umeyama, Jing Wang, Alessandra Di Pietro, Manuela Schmidinger
Institutions: Niigata University, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Hamamatsu University, Hamamatsu University School of Medicine, Keio University, Pfizer (Japan), Pfizer (United States), Medical University of Vienna
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3135070041